Pulmonary Arterial Hypertension News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Addressing Unmet Needs in Pulmonary Arterial Hypertension - MedPage Today



Addressing Unmet Needs in Pulmonary Arterial Hypertension 
MedPage Today
Pulmonary arterial hypertension (PAH) remains a complex disease with many clinical challenges for physicians, including early recognition, accurate diagnosis, and delayed initiation of PAH-specific pharmacotherapy. Despite treatment advances, mortality ...

 


Assessment of Ambrisentan in Pulmonary Arterial Hypertension - The Cardiology Advisor



The Cardiology Advisor
 
Assessment of Ambrisentan in Pulmonary Arterial Hypertension 
The Cardiology Advisor
Ambrisentan (Volibris®; GlaxoSmithKline) is safe, tolerable, and possibly effective for improving hemodynamics in patients with pulmonary arterial hypertension (PAH), according to an interim report on a postmarketing surveillance study published in ...

 


Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results - Lung Disease News



Lung Disease News
 
Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results 
Lung Disease News
Eiger BioPharmaceuticals will discontinue the development of ubenimex as a therapy for pulmonary arterial hypertension (PAH) due to disappointing results in the Phase 2 LIBERTY clinical trial. The treatment failed to improve PAH patients' pulmonary ...

 


Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet ... - PR Newswire (press release)



Rare Disease Report
 
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet ... 
PR Newswire (press release)
PALO ALTO, Calif., Jan. 16, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today Phase 2 LIBERTY study results in pulmonary ...
Phase 2 in Pulmonary Arterial Hypertension Fails to Meet Endpoints Rare Disease Report
Eiger BioPharmaceuticals Halts Clinical Development of Ubenimex for PAH Pulmonary Hypertension News
Eiger to abandon blood pressure drug after trial failure Reuters
Xconomy  -FierceBiotech  -Nasdaq  -Zacks Investment Research 
all 68 news articles » 


OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecasts to 2026 - PR Newswire (press release)



OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecasts to 2026 
PR Newswire (press release)
Pulmonary arterial hypertension (PAH) is a rare, fatal cardiopulmonary disease with an annual mortality rate of 15%. The disease is a subset (Group 1) within the World Health Organization's (WHO's) classification of the different types of pulmonary ...
EpiCast Report: Pulmonary Arterial Hypertension ? Epidemiology Forecast to 2026 satPRnews (press release)
Pulmonary Arterial Hypertension: Market Insights, Epidemiology and Market Forecast to 2027 MilTech

all 3 news articles » 


Global Cardiovascular Disease Drugs Market 2017-2023 - Expiries ... - Business Wire (press release)



Global Cardiovascular Disease Drugs Market 2017-2023 - Expiries ... 
Business Wire (press release)
Global Cardiovascular Disease Drugs Market to 2023 provides an introduction to cardiovascular disease (CVD), including disease symptoms, diagnosis, etiology, pathophysiology, comorbidities and complications, epidemiology, prognosis and treatment. CVD ...

and more » 


Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients with ... - Business Wire (press release)



Liquidia Initiates Phase 3 Clinical Trial of LIQ861 in Patients with ... 
Business Wire (press release)
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company focused on improving the performance of medicine by precisely engineering drug particles, today announced the initiation of a ...

and more » 


Pulmonary Arterial Hypertension (PAH) Market by Key Players, Product and Production Information analysis and ... - GEOPOLMonitor



GEOPOLMonitor
 
Pulmonary Arterial Hypertension (PAH) Market by Key Players, Product and Production Information analysis and ... 
GEOPOLMonitor
Pulmonary Arterial Hypertension (PAH) Market report based on delivery model, application, services, and geography. A detailed analysis of the key industry players has been done to provide insights into their business, products and services, and key ...

and more » 


Tracleer Seen to Benefit People with PH Due to IPF, Early Trial Data Shows - Pulmonary Hypertension News



Pulmonary Hypertension News
 
Tracleer Seen to Benefit People with PH Due to IPF, Early Trial Data Shows 
Pulmonary Hypertension News
But, as the study noted, there are no approved therapies to treat ?patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung.? Previous studies have suggested that PAH ...

 


Lupus Patients with PAH Have Relatively Good Survival Rates ... - Lupus News Today



Lupus Patients with PAH Have Relatively Good Survival Rates ... 
Lupus News Today
A retrospective study shows that 83.9% of patients suffering from SLE and pulmonary arterial hypertension (PAH) survive at least five years after diagnosis.
Pulmonary Arterial Hypertension (PAH) Market Report 2025 for ... satPRnews (press release)
Pulmonary Arterial Hypertension (PAH) Drugs Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast ... MilTech

all 7 news articles »